Pages that link to "Q46477675"
Jump to navigation
Jump to search
The following pages link to Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy (Q46477675):
Displaying 50 items.
- L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infants (Q26829856) (← links)
- Treatment-related biomarkers in pulmonary hypertension (Q28081276) (← links)
- Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. (Q33265103) (← links)
- AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension (Q33362326) (← links)
- Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension (Q33372442) (← links)
- Exhaled nitric oxide in diagnosis and management of respiratory diseases (Q33568617) (← links)
- Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells (Q33703652) (← links)
- Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension (Q33892575) (← links)
- Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension. (Q35153029) (← links)
- Arginine metabolic endotypes in pulmonary arterial hypertension. (Q35517452) (← links)
- An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications (Q35534747) (← links)
- Alterations of cellular bioenergetics in pulmonary artery endothelial cells (Q35611704) (← links)
- Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury (Q35855126) (← links)
- Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension (Q36303871) (← links)
- Update in pulmonary hypertension 2005. (Q36403168) (← links)
- Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers (Q36543145) (← links)
- Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats. (Q36568847) (← links)
- An Overview of Fractional Exhaled Nitric Oxide and Children with Asthma (Q36814010) (← links)
- Possible role of nitric oxide in the pathogenesis of pulmonary hypertension in broilers: a synopsis (Q36874431) (← links)
- High levels of hyaluronan in idiopathic pulmonary arterial hypertension (Q36977316) (← links)
- Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension (Q37071749) (← links)
- Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension (Q37112033) (← links)
- HIF2α-arginase axis is essential for the development of pulmonary hypertension. (Q37161630) (← links)
- Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging (Q37406369) (← links)
- Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. (Q37406383) (← links)
- Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension (Q37555347) (← links)
- Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis (Q37555421) (← links)
- Breath analysis in pulmonary arterial hypertension (Q37615204) (← links)
- Combination therapy in pulmonary arterial hypertension: do we have the right strategy? (Q37867668) (← links)
- Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension (Q38043810) (← links)
- Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension. (Q38112040) (← links)
- Application of nitric oxide measurements in clinical conditions beyond asthma (Q38670757) (← links)
- Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors (Q40919790) (← links)
- Decreased exhaled nitric oxide levels in patients with mitochondrial disorders (Q41811395) (← links)
- Riociguat: PATENT-1 Study (Q41980644) (← links)
- L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats (Q43136761) (← links)
- Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. (Q45198254) (← links)
- A urinary test for pulmonary arterial hypertension? (Q46616178) (← links)
- Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension (Q47111545) (← links)
- Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study. (Q47398434) (← links)
- Mitochondrial dysfunction and pulmonary hypertension: Cause, Effect or Both. (Q47726007) (← links)
- Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension (Q48185493) (← links)
- Endothelial Cell Metabolism. (Q49787990) (← links)
- Genistein attenuates hypoxic pulmonary hypertension via enhanced nitric oxide signaling and the erythropoietin system. (Q54362085) (← links)
- Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline. (Q55331942) (← links)
- Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension (Q58702183) (← links)
- Pulmonary Hypertension Is a Probable NO/ONOO− Cycle Disease: A Review (Q58998388) (← links)
- Chronic Ulcers in Thromboangiitis Obliterans (Buerger's Disease): Updating Epidemiology, Physiopathology, and Bosentan—A Novel Strategy of Therapy (Q59034900) (← links)
- Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension (Q91825809) (← links)
- Specific O-GlcNAc modification at Ser-615 modulates eNOS function (Q99629119) (← links)